Shots:

• The companies collaborated to evaluate the safety- tolerability & efficacy of Verastem’s VS-6766 + Amgen’s Lumakras in the P-I/II trial for patients with KRAS G12C-mutant NSCLC who have not been previously treated with a KRAS G12C inhibitor & who have progressed on a KRAS G12C inhibitor. The trial is expected to start at the end of 2021
• The study will investigate the potential benefits of a more complete vertical blockade of the RAS pathway with VS-6766 + Lumakras
• VS-6766 (CH5126766 & RO5126766) is a RAF/MEK inhibitor & has received BTD from the US FDA in combination with defactinib to treat patients with recurrent LGSOC. Lumakras is a KRAS G12C inhibitor

  | Ref: Verastem | Image: Verastem